Compare Rush Street Interactive Inc (RSI) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Rush Street Interactive Inc vs Recursion Pharmaceuticals Inc — how do they compare? Rush Street Interactive Inc trades at $33.46 (market cap $3.55B), while Recursion Pharmaceuticals Inc trades at $3.07 (market cap $1.53B). The key difference: Rush Street Interactive Inc is far larger — about 2.3× Recursion Pharmaceuticals Inc's market cap, and Rush Street Interactive Inc is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| RSI | RXRX | |
|---|---|---|
Market Cap | $3.55B | $1.53B |
Sector | Technology | Health |
52-Week High | $34.52 | $6.79 |
52-Week Low | $14.55 | $2.84 |
Enterprise Value | $3.23B | $946.50M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Rush Street Interactive (RSI) trades at $34.52, up 6.22% over 24 hours, with a bullish technical signal from moving averages and neutral oscillators. The company reported Q1 2026 EPS of $0.14, beating expectations, and maintains strong revenue growth projections for 2026. Recent expansion into Alberta and positive analyst coverage highlight operational momentum amid a high valuation multiple.
Outlook remains positive with 77% analyst buy ratings and a consensus price target of $30.44, though the stock trades above target. Risks include elevated P/E of 95.59 and net margin pressure at 2.98%. Earnings on July 29, 2026, will be critical for validating growth trajectory amid competitive and regulatory headwinds.
RXRX trades at $2.89, down 1.87% on the day, reflecting a challenging fundamental backdrop with a net income margin of -851.51% and negative cash flow from operations. The technical picture is bearish, though the stock has beaten earnings estimates for the last three quarters. Recent news highlights its AI-driven drug discovery platform and significant institutional interest, including purchases by Cathie Wood's Ark Invest.
The outlook remains speculative; the high analyst price target of $7.83 suggests significant upside potential, but this is contingent on the company successfully commercializing its pipeline. Key risks include persistent cash burn, intense competition, and the inherent uncertainty of clinical-stage biotech development.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Rush Street Interactive Inc
Rush Street Interactive, Inc. is a digital gaming and sports betting company operating in the regulated U.S. and international markets. The company owns and operates online casino (iGaming) and sports wagering platforms, including BetRivers and PlaySugarHouse brands. RSI focuses on providing a secure and high-quality online gaming experience, leveraging its proprietary technology platform and commitment to responsible gaming.
Read more on RSI →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
